APO Research
Talk to an analyst

APO RESEARCH · REPORT

Extended-release Medication

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Extended-release Medication Market Outlook and Growth Opportunities 2026

22 December 2025198 pages

Choose your research edition.

Industry ResearchExtended-release Medication Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Extended-release Medication Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Extended-release Medication Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Extended-release Medication Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Extended-release Medication Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Extended-release Medication market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Extended-release Medication is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Extended-release Medication is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Extended-release Medication is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Extended-release Medication market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Extended-release Medication market include Shanghai Shyndec Pharmaceutical, Takeda, Sanofi, Zhuhai Rundu Pharmaceutical, Johnson & Johnson, Novartis, Pfizer, Bayer and AbbVie, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Extended-release Medication market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Extended-release Medication and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Extended-release Medication revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Extended-release Medication market.

Extended-release Medication Segment by Company

Shanghai Shyndec Pharmaceutical

Takeda

Sanofi

Zhuhai Rundu Pharmaceutical

Johnson & Johnson

Novartis

Pfizer

Bayer

AbbVie

AstraZeneca

Endo Pharmaceuticals

Collegium Pharmaceutical, Inc

China Res Double-Crane

Extended-release Medication Segment by Type

Original Medication

Generic Medication

Extended-release Medication Segment by Application

Hospital

Drugstore

Other

Extended-release Medication Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Extended-release Medication status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Extended-release Medication key companies, revenue, market share, and recent developments.

3. To split the Extended-release Medication breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Extended-release Medication market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Extended-release Medication significant trends, drivers, influence factors in global and regions.

6. To analyze Extended-release Medication competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Extended-release Medication market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Extended-release Medication and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Extended-release Medication.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Extended-release Medication industry.

Chapter 3: Detailed analysis of Extended-release Medication company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Extended-release Medication in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Extended-release Medication in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Extended-release Medication Industry Trends Table 2. Extended-release Medication Industry Drivers Table 3. Extended-release Medication Industry Opportunities and Challenges Table 4. Extended-release Medication Industry Restraints Table 5. Global Extended-release Medication Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Extended-release Medication Revenue Share by Company (2021-2026) Table 7. Global Extended-release Medication Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Extended-release Medication Key Company Manufacturing Base & Headquarters Table 9. Global Extended-release Medication Company, Product Type & Application Table 10. Global Extended-release Medication Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Extended-release Medication by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Original Medication Table 15. Significant Companies of Generic Medication Table 16. Global Extended-release Medication Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Extended-release Medication Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Extended-release Medication Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Extended-release Medication Sales Value Share by Type (2021-2026) Table 20. Global Extended-release Medication Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Drugstore Table 23. Significant Companies of Other Table 24. Global Extended-release Medication Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Extended-release Medication Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Extended-release Medication Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Extended-release Medication Sales Value Share by Application (2021-2026) Table 28. Global Extended-release Medication Sales Value Share by Application (2027-2032) Table 29. Global Extended-release Medication Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Extended-release Medication Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Extended-release Medication Sales Value Share by Region (2021-2026) Table 32. Global Extended-release Medication Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Extended-release Medication Sales Value Share by Region (2027-2032) Table 34. Global Extended-release Medication Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Extended-release Medication Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Extended-release Medication Sales Value Market Share by Country (2021-2026) Table 37. Global Extended-release Medication Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Extended-release Medication Sales Value Market Share by Country (2027-2032) Table 39. Shanghai Shyndec Pharmaceutical Company Information Table 40. Shanghai Shyndec Pharmaceutical Business Overview Table 41. Shanghai Shyndec Pharmaceutical Extended-release Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Shanghai Shyndec Pharmaceutical Extended-release Medication Product Portfolio Table 43. Shanghai Shyndec Pharmaceutical Recent Development Table 44. Takeda Company Information Table 45. Takeda Business Overview Table 46. Takeda Extended-release Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Takeda Extended-release Medication Product Portfolio Table 48. Takeda Recent Development Table 49. Sanofi Company Information Table 50. Sanofi Business Overview Table 51. Sanofi Extended-release Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Sanofi Extended-release Medication Product Portfolio Table 53. Sanofi Recent Development Table 54. Zhuhai Rundu Pharmaceutical Company Information Table 55. Zhuhai Rundu Pharmaceutical Business Overview Table 56. Zhuhai Rundu Pharmaceutical Extended-release Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Zhuhai Rundu Pharmaceutical Extended-release Medication Product Portfolio Table 58. Zhuhai Rundu Pharmaceutical Recent Development Table 59. Johnson & Johnson Company Information Table 60. Johnson & Johnson Business Overview Table 61. Johnson & Johnson Extended-release Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Johnson & Johnson Extended-release Medication Product Portfolio Table 63. Johnson & Johnson Recent Development Table 64. Novartis Company Information Table 65. Novartis Business Overview Table 66. Novartis Extended-release Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Novartis Extended-release Medication Product Portfolio Table 68. Novartis Recent Development Table 69. Pfizer Company Information Table 70. Pfizer Business Overview Table 71. Pfizer Extended-release Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Pfizer Extended-release Medication Product Portfolio Table 73. Pfizer Recent Development Table 74. Bayer Company Information Table 75. Bayer Business Overview Table 76. Bayer Extended-release Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Bayer Extended-release Medication Product Portfolio Table 78. Bayer Recent Development Table 79. AbbVie Company Information Table 80. AbbVie Business Overview Table 81. AbbVie Extended-release Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. AbbVie Extended-release Medication Product Portfolio Table 83. AbbVie Recent Development Table 84. AstraZeneca Company Information Table 85. AstraZeneca Business Overview Table 86. AstraZeneca Extended-release Medication Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. AstraZeneca Extended-release Medication Product Portfolio Table 88. AstraZeneca Recent Development Table 89. Endo Pharmaceuticals Company Information Table 90. Endo Pharmaceuticals Business Overview Table 91. Endo Pharmaceuticals Extended-release Medication Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Endo Pharmaceuticals Extended-release Medication Product Portfolio Table 93. Endo Pharmaceuticals Recent Development Table 94. Collegium Pharmaceutical, Inc Company Information Table 95. Collegium Pharmaceutical, Inc Business Overview Table 96. Collegium Pharmaceutical, Inc Extended-release Medication Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Collegium Pharmaceutical, Inc Extended-release Medication Product Portfolio Table 98. Collegium Pharmaceutical, Inc Recent Development Table 99. China Res Double-Crane Company Information Table 100. China Res Double-Crane Business Overview Table 101. China Res Double-Crane Extended-release Medication Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. China Res Double-Crane Extended-release Medication Product Portfolio Table 103. China Res Double-Crane Recent Development Table 104. Research Programs/Design for This Report Table 105. Authors List of This Report Table 106. Secondary Sources Table 107. Primary Sources List of Figures Figure 1. Extended-release Medication Product Image Figure 2. Global Extended-release Medication Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Extended-release Medication Market Size (2021-2032) & (US$ Million) Figure 4. Global Extended-release Medication Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Original Medication Image Figure 8. Generic Medication Image Figure 9. Global Extended-release Medication Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Extended-release Medication Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Extended-release Medication Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Drugstore Image Figure 14. Other Image Figure 15. Global Extended-release Medication Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Extended-release Medication Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Extended-release Medication Sales Value Share by Application (2021-2032) Figure 18. Global Extended-release Medication Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Extended-release Medication Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Extended-release Medication Sales Value (2021-2032) & (US$ Million) Figure 21. North America Extended-release Medication Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Extended-release Medication Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Extended-release Medication Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Extended-release Medication Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Extended-release Medication Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Extended-release Medication Sales Value (2021-2032) & (US$ Million) Figure 27. South America Extended-release Medication Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Extended-release Medication Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Extended-release Medication Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Extended-release Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Extended-release Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Extended-release Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Extended-release Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Extended-release Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Extended-release Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Extended-release Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Extended-release Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Extended-release Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Extended-release Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Extended-release Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Extended-release Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Extended-release Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Extended-release Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Extended-release Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Extended-release Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Extended-release Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Extended-release Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Extended-release Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Extended-release Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Extended-release Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Extended-release Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Extended-release Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Extended-release Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Extended-release Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Extended-release Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Extended-release Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Extended-release Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Extended-release Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Extended-release Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Extended-release Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Extended-release Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Extended-release Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Extended-release Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Extended-release Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Extended-release Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Extended-release Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Extended-release Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Extended-release Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Extended-release Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Extended-release Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Extended-release Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Extended-release Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Extended-release Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Extended-release Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Extended-release Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Extended-release Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Extended-release Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Extended-release Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Extended-release Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Extended-release Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Extended-release Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Extended-release Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Extended-release Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Extended-release Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Extended-release Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Extended-release Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Extended-release Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Extended-release Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Extended-release Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Extended-release Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Extended-release Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Extended-release Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Extended-release Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Extended-release Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Extended-release Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Extended-release Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Extended-release Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Extended-release Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Extended-release Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Extended-release Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Extended-release Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Extended-release Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Extended-release Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Extended-release Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Extended-release Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Extended-release Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Extended-release Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Extended-release Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Extended-release Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Extended-release Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Extended-release Medication Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Extended-release Medication Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Extended-release Medication Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Original Medication
  • Generic Medication
Applications
  • Hospital
  • Drugstore
  • Other
Companies covered
  • Shanghai Shyndec Pharmaceutical
  • Takeda
  • Sanofi
  • Zhuhai Rundu Pharmaceutical
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • Bayer
  • AbbVie
  • AstraZeneca
  • Endo Pharmaceuticals
  • Collegium Pharmaceutical, Inc
  • China Res Double-Crane

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Extended-release Medication Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Extended-release Medication Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Extended-release Medication Market Dynamics
  1. 2.1 Extended-release Medication Industry Trends
  2. 2.2 Extended-release Medication Industry Drivers
  3. 2.3 Extended-release Medication Industry Opportunities and Challenges
  4. 2.4 Extended-release Medication Industry Restraints
3 Extended-release Medication Market by Company
  1. 3.1 Global Extended-release Medication Company Revenue Ranking in 2025
  2. 3.2 Global Extended-release Medication Revenue by Company (2021-2026)
  3. 3.3 Global Extended-release Medication Company Ranking (2024-2026)
  4. 3.4 Global Extended-release Medication Company Manufacturing Base and Headquarters
  5. 3.5 Global Extended-release Medication Company Product Type and Application
  6. 3.6 Global Extended-release Medication Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Extended-release Medication Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Extended-release Medication Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Extended-release Medication Market by Type
  1. 4.1 Extended-release Medication Type Introduction
  2. 4.1.1 Original Medication
  3. 4.1.2 Generic Medication
  4. 4.2 Global Extended-release Medication Sales Value by Type
  5. 4.2.1 Global Extended-release Medication Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Extended-release Medication Sales Value by Type (2021-2032)
  7. 4.2.3 Global Extended-release Medication Sales Value Share by Type (2021-2032)
5 Extended-release Medication Market by Application
  1. 5.1 Extended-release Medication Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Drugstore
  4. 5.1.3 Other
  5. 5.2 Global Extended-release Medication Sales Value by Application
  6. 5.2.1 Global Extended-release Medication Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Extended-release Medication Sales Value by Application (2021-2032)
  8. 5.2.3 Global Extended-release Medication Sales Value Share by Application (2021-2032)
6 Extended-release Medication Regional Value Analysis
  1. 6.1 Global Extended-release Medication Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Extended-release Medication Sales Value by Region (2021-2032)
  3. 6.2.1 Global Extended-release Medication Sales Value by Region: 2021-2026
  4. 6.2.2 Global Extended-release Medication Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Extended-release Medication Sales Value (2021-2032)
  7. 6.3.2 North America Extended-release Medication Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Extended-release Medication Sales Value (2021-2032)
  10. 6.4.2 Europe Extended-release Medication Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Extended-release Medication Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Extended-release Medication Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Extended-release Medication Sales Value (2021-2032)
  16. 6.6.2 South America Extended-release Medication Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Extended-release Medication Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Extended-release Medication Sales Value Share by Country, 2025 VS 2032
7 Extended-release Medication Country-level Value Analysis
  1. 7.1 Global Extended-release Medication Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Extended-release Medication Sales Value by Country (2021-2032)
  3. 7.2.1 Global Extended-release Medication Sales Value by Country (2021-2026)
  4. 7.2.2 Global Extended-release Medication Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Extended-release Medication Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Extended-release Medication Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Extended-release Medication Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Extended-release Medication Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Extended-release Medication Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Extended-release Medication Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Extended-release Medication Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Extended-release Medication Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Extended-release Medication Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Extended-release Medication Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Extended-release Medication Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Extended-release Medication Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Extended-release Medication Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Extended-release Medication Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Extended-release Medication Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Extended-release Medication Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Extended-release Medication Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Extended-release Medication Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Extended-release Medication Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Extended-release Medication Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Extended-release Medication Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Extended-release Medication Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Extended-release Medication Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Extended-release Medication Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Extended-release Medication Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Extended-release Medication Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Extended-release Medication Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Extended-release Medication Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Extended-release Medication Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Extended-release Medication Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Extended-release Medication Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Extended-release Medication Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Extended-release Medication Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Extended-release Medication Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Extended-release Medication Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Extended-release Medication Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Extended-release Medication Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Extended-release Medication Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Extended-release Medication Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Extended-release Medication Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Extended-release Medication Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Extended-release Medication Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Extended-release Medication Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Extended-release Medication Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Extended-release Medication Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Extended-release Medication Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Extended-release Medication Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Extended-release Medication Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Extended-release Medication Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Extended-release Medication Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Extended-release Medication Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Extended-release Medication Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Extended-release Medication Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Extended-release Medication Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Extended-release Medication Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Extended-release Medication Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Extended-release Medication Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Extended-release Medication Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Extended-release Medication Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Extended-release Medication Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Extended-release Medication Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Extended-release Medication Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Extended-release Medication Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Extended-release Medication Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Extended-release Medication Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Extended-release Medication Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Extended-release Medication Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Extended-release Medication Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Extended-release Medication Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Extended-release Medication Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Extended-release Medication Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Extended-release Medication Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Extended-release Medication Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Extended-release Medication Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Extended-release Medication Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Extended-release Medication Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Extended-release Medication Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Extended-release Medication Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Extended-release Medication Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Extended-release Medication Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Extended-release Medication Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Extended-release Medication Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Extended-release Medication Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Extended-release Medication Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Shanghai Shyndec Pharmaceutical
  2. 8.1.1 Shanghai Shyndec Pharmaceutical Company Information
  3. 8.1.2 Shanghai Shyndec Pharmaceutical Business Overview
  4. 8.1.3 Shanghai Shyndec Pharmaceutical Extended-release Medication Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Shanghai Shyndec Pharmaceutical Extended-release Medication Product Portfolio
  6. 8.1.5 Shanghai Shyndec Pharmaceutical Recent Developments
  7. 8.2 Takeda
  8. 8.2.1 Takeda Company Information
  9. 8.2.2 Takeda Business Overview
  10. 8.2.3 Takeda Extended-release Medication Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Takeda Extended-release Medication Product Portfolio
  12. 8.2.5 Takeda Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Extended-release Medication Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Extended-release Medication Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Zhuhai Rundu Pharmaceutical
  20. 8.4.1 Zhuhai Rundu Pharmaceutical Company Information
  21. 8.4.2 Zhuhai Rundu Pharmaceutical Business Overview
  22. 8.4.3 Zhuhai Rundu Pharmaceutical Extended-release Medication Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Zhuhai Rundu Pharmaceutical Extended-release Medication Product Portfolio
  24. 8.4.5 Zhuhai Rundu Pharmaceutical Recent Developments
  25. 8.5 Johnson & Johnson
  26. 8.5.1 Johnson & Johnson Company Information
  27. 8.5.2 Johnson & Johnson Business Overview
  28. 8.5.3 Johnson & Johnson Extended-release Medication Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Johnson & Johnson Extended-release Medication Product Portfolio
  30. 8.5.5 Johnson & Johnson Recent Developments
  31. 8.6 Novartis
  32. 8.6.1 Novartis Company Information
  33. 8.6.2 Novartis Business Overview
  34. 8.6.3 Novartis Extended-release Medication Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Novartis Extended-release Medication Product Portfolio
  36. 8.6.5 Novartis Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Extended-release Medication Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Extended-release Medication Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 Bayer
  44. 8.8.1 Bayer Company Information
  45. 8.8.2 Bayer Business Overview
  46. 8.8.3 Bayer Extended-release Medication Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Bayer Extended-release Medication Product Portfolio
  48. 8.8.5 Bayer Recent Developments
  49. 8.9 AbbVie
  50. 8.9.1 AbbVie Company Information
  51. 8.9.2 AbbVie Business Overview
  52. 8.9.3 AbbVie Extended-release Medication Revenue and Gross Margin (2021-2026)
  53. 8.9.4 AbbVie Extended-release Medication Product Portfolio
  54. 8.9.5 AbbVie Recent Developments
  55. 8.10 AstraZeneca
  56. 8.10.1 AstraZeneca Company Information
  57. 8.10.2 AstraZeneca Business Overview
  58. 8.10.3 AstraZeneca Extended-release Medication Revenue and Gross Margin (2021-2026)
  59. 8.10.4 AstraZeneca Extended-release Medication Product Portfolio
  60. 8.10.5 AstraZeneca Recent Developments
  61. 8.11 Endo Pharmaceuticals
  62. 8.11.1 Endo Pharmaceuticals Company Information
  63. 8.11.2 Endo Pharmaceuticals Business Overview
  64. 8.11.3 Endo Pharmaceuticals Extended-release Medication Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Endo Pharmaceuticals Extended-release Medication Product Portfolio
  66. 8.11.5 Endo Pharmaceuticals Recent Developments
  67. 8.12 Collegium Pharmaceutical, Inc
  68. 8.12.1 Collegium Pharmaceutical, Inc Company Information
  69. 8.12.2 Collegium Pharmaceutical, Inc Business Overview
  70. 8.12.3 Collegium Pharmaceutical, Inc Extended-release Medication Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Collegium Pharmaceutical, Inc Extended-release Medication Product Portfolio
  72. 8.12.5 Collegium Pharmaceutical, Inc Recent Developments
  73. 8.13 China Res Double-Crane
  74. 8.13.1 China Res Double-Crane Company Information
  75. 8.13.2 China Res Double-Crane Business Overview
  76. 8.13.3 China Res Double-Crane Extended-release Medication Revenue and Gross Margin (2021-2026)
  77. 8.13.4 China Res Double-Crane Extended-release Medication Product Portfolio
  78. 8.13.5 China Res Double-Crane Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst